Therefore, considering the poor prognosis of SKCM patients in high-SCARB1 subgroup, we hypothesized that SKCM patients in the high-SCARB1 subgroup exhibit a higher degree of immunosuppression, and SCARB1 may promote tumor occurrence and development in SKCM by affecting the recruitment and activation of immune cells. The gene discussed is SCARB1; the disease is neoplasm.